Overview

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

Status:
COMPLETED
Trial end date:
2024-12-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects
Phase:
PHASE1
Details
Lead Sponsor:
Daiichi Sankyo
Treatments:
quizartinib
rufinamide